Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 75348780

Next Previous
Drug Profile

JNJ 75348780

Alternative Names: JNJ-75348780; JNJ-8780

Latest Information Update: 17 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TeneoBio
  • Developer Janssen Biotech
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Dec 2024 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in Greece, Ukraine, Poland, Moldova, Japan, Georgia, Belgium (SC) (NCT06788509)
  • 30 Dec 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Ukraine, Poland, Japan, Moldova, Greece, Georgia, Belgium (SC) (NCT06788509)
  • 31 Oct 2024 JNJ 75348780 is still in phase I trial for Chronic-lymphocytic-leukaemia (Second-line therapy or greater) in Australia, France, South Korea, Taiwan, Israel, USA, Spain, United Kingdom (SC) (NCT04540796)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top